The panels were designed to identify cytotoxic T cells (CD8+ GZMB+ CD3+), myeloid-derived suppressor cells (MDSCs) (CD11b+ CD33+ HLA-DR-negative) and B cells (CD20+ CD79a+, Figure 4B, Supplemental Figure S1), as well as a panel with CD3 and FOS to confirm the high expression of FOS in the tumour cells. This evidence concerns the gene CD33 and neoplasm.